http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113768892-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d98b138c645573edf06eb4d49530872d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-397 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 |
| filingDate | 2021-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_197e8cfd680480eaaf9e69c179ed8692 |
| publicationDate | 2021-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113768892-A |
| titleOfInvention | A tablet composition for treating cardiovascular diseases, and its preparation method |
| abstract | The invention provides a tablet composition for treating cardiovascular diseases and a preparation method thereof. The ezetimibe freeze-dried powder is prepared by freeze-drying ezetimibe and sulfobutyl-beta-cyclodextrin derivatives, the sulfobutyl-beta-cyclodextrin derivatives are sulfobutyl betacyclodextrin sodium modified by 4-methylbutyrolactone, and the molar ratio of the ezetimibe to the sulfobutyl betacyclodextrin sodium modified by the 4-methylbutyrolactone is 1: 2.2-2.8. The filler consists of microcrystalline cellulose and hydroxypropyl cellulose, wherein the weight ratio of the microcrystalline cellulose to the hydroxypropyl cellulose is 1: 1.7-2.3; the lubricant is magnesium stearate. According to the ezetimibe-containing tablet composition for treating cardiovascular diseases, the dissolution rate of 30min is not lower than 90%, preferably the dissolution rate of 15min is not lower than 90% in hydrochloric acid solution with the pH value of 1.2, the bioavailability is high, the treatment effect of the ezetimibe is greatly guaranteed, and the clinical treatment effect is remarkably improved; the degradation product has low content of impurity A and impurity B and stable quality after being placed for 6 months under the accelerated condition. |
| priorityDate | 2021-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.